Myriam Chalabi: Patients with stage 1c TNBC with high TILs have an excellent prognosis without chemo
Myriam Chalabi, Medical Oncologist and Cancer Immunotherapy researcher at Antoni van Leeuwenhoek, shared a post on their X:
“Patients with stage 1c TNBC (Triple Negative Breast Cancer) with high TILs (Tumor-infiltrating lymphocytes) (>50%) have an excellent prognosis (10yr survival 95%) without chemo!
Congratulations Marleen KokLab and team for this important work to better select patients who need chemo, and more importantly, those who do not.”
Source: Myriam Chalabi/X
Myriam Chalabi is a Gastrointestinal Oncologist and clinician scientist at the Netherlands Cancer Institute in Amsterdam. In 2022 she was named one of the 11 early career researchers to watch by Nature Medicine. In 2023 she was awarded the ESMO José Baselga Fellowship for Clinician Scientists.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023